

Reply to the comment on: Cancer-associated myositis before and after the COVID-19 pandemic onset

Sirs,

We would like to acknowledge the ideas from Costa *et al.* (1) shared on our letter (2). Clearly the problem of cancer-associated myositis and its interrelationship with the COVID-19 pandemic onset is an interesting issue for further study. We agree with many of the points they have made and thank them for giving more information about the findings of the study. We recognise that doing more research with a larger cohort and looking more deeply into the details would help confirm these results and give better evidence-based information for taking care of patients in the future. Additionally, it would be interesting to assess the potential impact of other risk factors, such as medication use, immunological status, diagnostic testing, on the severity

of myositis, which requires further investigation. Broader population studies and in-depth analyses will confirm the results and provide more evidence-based information for future patient management.

H. DAUNGSUPAWONG¹, PhD
V. WIWANITKIT², MD

¹Private Academic Consultant, Phonhong,
Lao People's Democratic Republic.
²Department of Research Analytics, Saveetha
Dental College and Hospitals, Saveetha
Institute of Medical and Technical Sciences,
Saveetha University, Chennai, India.

ORCID iD

H. Daungsupawong: 0009-0002-5881-2709
V. Wiwanitkit: 0000-0003-1039-3728

Please address correspondence to:
Hinpetch Daungsupawong
Private Academic Consultant,
Phonhong, Vientiane 10000,
Lao People's Democratic Republic.
E-mail: hinpetchdaung@gmail.com
Competing interests: none declared.

© Copyright CLINICAL AND
EXPERIMENTAL RHEUMATOLOGY 2026.

References

1. COSTA FM, CAMPANILHO-MARQUES R, DOURADO E *et al.*: Comment on: Cancer-associated myositis before and after the COVID-19 pandemic onset: a comment. *Clin Exp Rheumatol* 2026; 44(2): 419.
2. DAUNGSUPAWONG H, WIWANITKIT V: Cancer-associated myositis before and after the COVID-19 pandemic onset: a comment. *Clin Exp Rheumatol* 2025; 43(2): 387.
<https://doi.org/10.55563/clinexprheumatol/mxdet4>